Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.89 |
| ▸ | MEN1 | O00255 | 3/20 | 0.89 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.89 |
| ▸ | HPGD | P15428 | 2/20 | 0.89 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.89 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.89 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | APP | P05067 | 1/20 | 0.78 |
| ▸ | MAOB | P27338 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | MAOA | P21397 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5082144 | 0.94 | MAPT (1.00) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL5082149 | 0.94 | MAPT (1.00) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL17220889 | 0.91 | MAPT (0.80) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL17220887 | 0.91 | MAPT (0.80) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL5422587 | 0.91 | MAPT (0.80) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL5422585 | 0.91 | MAPT (0.80) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL28906330 | 0.90 | APP (0.81) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL29394621 | 0.90 | MAPT (0.72) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL14920160 | 0.90 | MAPT (0.72) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 | |
| SCHEMBL14920158 | 0.90 | MAPT (0.72) | MAPTMEN1MAPK1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163013-A1 | TREATMENT OF GENITOURINARY SYNDROME OF MENOPAUSE | NORDEEN, Steven | 2025-05-22 | — | — | US | disclosed |
| WO-2023147289-A1 | TREATMENT OF GENITOURINARY SYNDROME OF MENOPAUSE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163013-A1 | TREATMENT OF GENITOURINARY SYNDROME OF MENOPAUSE | SHBG, GSS, GPER1 | MAPT 2487/4885MEN1 287/4885MAPK1 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.